Background: Fibrotic stricture is a common complication of Crohn's disease (CD)
| INTRODUCTION
The lifetime risk of stricture is approximately 50% among patients with Crohn's disease (CD). 1 In addition to causing abdominal pain, distension, bloating and vomiting, evidence suggests that stricturing CD may precede the development of internal penetrating disease with fistula formation. 2, 3 Whilst there has been an unprecedented expansion in CD drug development over the last decade, novel and established treatments are primarily directed towards reducing inflammation. 4, 5 Anti-inflammatories may be effective in patients with small bowel strictures; 6 however, they do not specifically target or reverse fibrosis. Most often, stricturing CD is treated with surgical resection. 7 Unfortunately, post-operative disease recurrence and re-stricturing are common. 8 Effective drug therapy to prevent and treat CD-associated strictures is therefore a substantial unmet medical need.
Multiple anti-fibrotic compounds are currently under evaluation for the treatment of liver, skin, kidney, heart and lung disease, 9 with 2 agents approved for use in patients with lung fibrosis (pirfenidone and nintedanib). 10, 11 In contrast, there have been no trials of antifibrotics in inflammatory bowel diseases (IBD). This lack of progress is potentially attributable to several factors, including heterogeneous disease definitions, diagnostic methods, clinical trial eligibility criteria and endpoints, and treatment targets. 12 We assembled a global, multidisciplinary panel of experts (the CrOhN'S disease anti-fibrotic STRICTure Therapies [CONSTRICT] group) and conducted a three-round consensus process using modified RAND/University of California Los Angeles (UCLA) appropriateness methodology 13, 14 with the aim of standardising assessment of CD strictures and treatment targets. Additionally, we developed a conceptual framework for the conduct of early-phase clinical trials of anti-fibrotic agents.
| MATERIALS AND METHODS

| Systematic review of literature
The systematic review and consensus process focused solely on small bowel strictures, since these are most common. 7 Furthermore, colonic strictures harbour the risk for malignancy 15 and accordingly, may not be a primary initial target for anti-fibrotic therapies.
PubMed, EMBASE and the Cochrane Library (CENTRAL) were searched from inception to July 31, 2017 to identify definitions, instruments and trial design features used for assessment of CDassociated strictures. Keywords included ('Crohn's disease' OR 'small bowel') AND ('stricture' OR 'fibrosis' OR 'stenosis' OR 'dilation'). A recursive search of bibliographies of relevant articles was also performed. Eligible studies enrolled adult patients (>18 years) and provided information on how stricture was defined, the modality of diagnosis and treatment target(s). Controlled trials, cohort studies, case-control studies and cross-sectional studies were included. NonEnglish language publications, case series and case reports were excluded. Modified RAND/UCLA appropriateness methodology was used to assess the face validity (the extent to which an item appears to address the concept it purports to measure) and feasibility of items identified in the systematic review. Additional items were included based upon the opinion of the panelists after distribution of the initial item list. RAND/UCLA appropriateness methodology employs a modified Delphi panel approach to combine the best available evidence with the clinical experience of relevant experts. 16 This process is widely accepted, iterative and evidence-based.
| First panel meeting and initial survey
Items identified by systematic review and an introductory panel meeting were circulated via an online survey. Panelists anonymously rated the appropriateness of each item on a scale from 1 to 9
(1 = inappropriate, 9 = highly appropriate).
| Second and third panel meeting and final survey
Results of the initial survey were distributed to panelists and discussed in a moderated teleconference. Areas of disagreement regarding item appropriateness were identified and panelists were asked to explain the rationale behind their responses. In accordance with RAND/UCLA appropriateness methodology, no attempt was made to force the panel to consensus. The survey was revised based on the second panel meeting to improve clarity and a second survey was circulated. One key item (#30) was chosen by the panel for re-discussion based on an unexpected disagreement in survey round two. The item was discussed via e-mail, and a third survey consisting only of this item was circulated.
| Analysis of panel results
Each survey item was classified as inappropriate, uncertain or appropriate based on the median panel rating and degree of panel disagreement (median 1-3 without disagreement = inappropriate; median 4-6 or any median with disagreement = uncertain; median 7-9 without disagreement = appropriate).
14 Disagreement was considered present when 2 or more panelists rated appropriateness in each extreme 3-point region (1-3 and 7-9).
3 | RESULTS
| Systematic review
The literature search retrieved a total of 2238 citations. After removing duplicates, 1518 citations were screened using predefined eligibility criteria. Of these, 1270 citations were deemed not applicable based on title and abstract review. Ninety studies were excluded during full-text review, leaving a total of 158 included studies ( Figure S1 ). (Tables S1-S4 ). These data, in addition to other items of potential importance, were subsequently incorporated into a survey and sent to panelists for appropriateness rating (Table S5 ).
| Consensus process
Panel discussion resulted in minimal edits to the proposed items and the addition of 2 new statements. Item #30 revealed an unexpected disagreement in round two and was re-discussed in a third round.
In the literature, the terms "stenosis" and "stricture" are used interchangeably. In this article, we defined "stricture" based upon the recommendation of the Consensus of the American Gastroenterology Association (AGA). 17 The term stricture encompasses the possibility of the co-existence of inflammatory and fibrotic components. Specific criteria were generated for each of the radiologic fea- Obstructive symptoms alone were determined to be insufficient to define a stricture (Table S5 ; Table 1 ).
| Definition of anastomotic small bowel stricture
Appropriateness ratings were similar for definitions of anastomotic (at site of prior intestinal resection with anastomosis) and na€ ıve small bowel strictures; however, there was uncertainty regarding the definitions of wall thickness (Table S5 ; Table 1 ). The authors were cautious about evaluation of small bowel anastomosis, as these definitions only apply to proximal small bowel unaltered by surgical intervention, not enteroenterostomy associated with side-to-side small bowel anastomosis.
| Diagnosis of small bowel stricturing CD
Cross-sectional imaging or ileocolonoscopy alone was considered appropriate to diagnose a small bowel stricture. Symptoms alone were considered inappropriate to diagnose a stricture. Moreover, most panelists felt that symptoms are not required to diagnose a stricture. Panelists felt that MR enterography (MRE) is the preferred diagnostic modality (sensitivity 55%-100%; specificity 91%-100%). 18 There was uncertainty about whether CT enterography (CTE) and ultrasound with or without oral contrast are the preferred diagnostic modalities. The high accuracy of both MRE and CTE was considered appropriate for detection of a single or multiple small bowel stricture(s), with CTE and MRE felt to have comparable accuracy. Ultrasound with or without oral contrast was deemed uncertain by the panel for detection of single or multiple small bowel stricture(s). MRE was preferred over CTE due to lack of radiation exposure in nonacutely ill, clinically stable patients (Table S5 ).
| Clinical symptoms of stricturing CD
Clinical symptoms are not highly correlated with the presence of small bowel strictures on cross-sectional imaging or endoscopy and there is a disconnect between clinical symptoms and the severity of small bowel strictures on cross-sectional imaging or endoscopy.
Symptoms considered appropriate for collection were acute
T A B L E 1 Select consensus definitions for diagnosis and improvement of Crohn's disease-associated small bowel strictures. Detailed definitions for key features on radiology and endoscopy are provided
Item
Median, panel score interquartile range Appropriateness
Definition of na€ ıve small bowel strictures
A na€ ıve small bowel stricture on cross-sectional imaging (CTE, MRE or ultrasound) is optimally defined as:
Localised luminal narrowing and bowel wall thickening with pre-stricture dilation.
8.0, 4.0 Appropriate
Definitions for luminal diameter in a na€ ıve stricture:
Luminal diameter reduction by at least 50%, measured relative to a normal adjacent appropriately distended bowel loop.
7.0, 2.0 Appropriate
Luminal diameter of < 1 cm in an appropriately distended lumen.
5.0, 4.0 Uncertain
Definitions for bowel wall thickening in a na€ ıve stricture:
Increase in wall thickness of 25% in the maximally thickened area, in an appropriately distended lumen, measured relative to a normal, adjacent, appropriately distended bowel loop.
7.0, 3.0 Appropriate > 3 mm with luminal distension in the maximally thickened area, in an appropriately distended lumen.
8.0, 2.0 Uncertain
Definitions for pre-stricture dilation in a na€ ıve stricture:
Bowel diameter that is 20% greater than the normal diameter in an appropriately distended lumen.
7.0, 2.0 Uncertain
Bowel diameter of greater than 3 cm 8.0, 2.0 Appropriate
Definition for na€ ıve stricture on endoscopy
Inability to pass an adult colonoscope through the narrowed area without prior endoscopic dilation and with a reasonable amount of pressure applied.
8.0, 2.0 Appropriate
Definition of anastomotic small bowel strictures
An anastomotic small bowel stricture on cross-sectional imaging (CTE, MRE or ultrasound) is optimally defined as:
8.0, 2.0 Appropriate
Definitions for luminal diameter in an anastomotic stricture:
7.0, 1.0 Appropriate
5.0, 3.0 Uncertain
Definitions for bowel wall thickening in an anastomotic stricture:
7.0, 4.0 Uncertain
> 3 mm with luminal distension in the maximally thickened area, in an appropriately distended lumen.
7.0, 3.0 Appropriate
Definitions for pre-stricture dilation:
Bowel diameter that is 20% greater than the normal diameter in an appropriately distended lumen. Inability to pass an adult colonoscope through the narrowed area without prior endoscopic dilation and with a reasonable amount of pressure applied. (Table S5 ).
| Detection of inflammation and fibrosis
In advanced small bowel strictures, extensive overlap between fibrotic and inflammatory components can be found on histopathology. 8 To detect the inflammatory component of a small bowel stricture, MRE and CTE were deemed to be highly accurate and clinical symptoms were felt to be highly inaccurate. There was uncertainty about ultrasound, colonoscopy, C-reactive protein (CRP) and faecal calprotectin for detection of the inflammatory component of a small bowel stricture. It was uncertain whether the degree of inflammation should optimally be determined using validated endoscopic scores.
Panelists rated the following imaging features, reflecting the inflammatory component of a small bowel stricture on cross-sectional imaging, as appropriate: mural hyperenhancement, presence of ulcers, co-existence with penetrating disease, perienteric fat stranding, comb sign and intramural T2 hyperintensity (for MRE only). [18] [19] [20] [21] [22] [23] It was uncertain whether delayed enhancement MRI, magnetisation transfer MRI, ultrasound elastography, contrast enhanced ultra- (1) a greater than 50% improvement in luminal narrowing or luminal diameter reduction of less than 50%; (2) reduction in bowel wall thickening by 50%; (3) reduction in pre-stricture dilation by 50%, a pre-stricture bowel diameter equal to normal bowel or a bowel diameter less than 2.5 cm and (4) improvement in stricture length by 50%. The ability to pass an adult endoscope through the stricture was felt to indicate successful anti-fibrotic treatment of a small bowel obstruction (Table 1 ).
In terms of time points to evaluate the efficacy of medical therapies for CD stricture on cross-sectional imaging, 24 and 48 weeks were considered appropriate, with 24 weeks chosen as the optimal primary efficacy endpoint for a clinical trial. Twenty-four weeks was also considered the only acceptable time point to evaluate endoscopic treatment success. Twelve weeks was considered the optimal time point to evaluate treatment success based on clinical symptom improvement (Table S5 ).
| Endoscopic treatment of a stricture as a starting point for a clinical trial in Crohn's disease
Endoscopic balloon dilation may be useful for treatment of symptomatic patients with obstruction and may be used to temporise symptoms in an anti-fibrotic trial. The following items were judged to be appropriate: 18 mm as the maximal luminal diameter after dilation in 1 or several sessions; a balloon inflation time of at least 1 minute; and 5 cm as the maximum stricture length that should be dilated. Technical success after dilation is defined as the ability to pass an adult ileocolonoscope through a previously nontraversable stricture with reasonable amount of pressure applied, clinical efficacy for dilation is defined as the relief of clinical symptoms of bowel obstruction after dilation. Comparable items were considered appropriate for anastomotic strictures. Graded-throughthe-scope balloons should be the preferred tool for endoscopic dilation (Table S5 ).
| Endpoints for failure of stricture therapy after initial response
There optimal clinical symptoms indicative of treatment failure or reobstruction of a small bowel stricture are abdominal distention, cramping, vomiting, dietary restrictions, abdominal pain and postprandial abdominal pain. A combination of pre-stricture dilation, wall thickening and luminal narrowing on radiology and the inability to pass an adult endoscope were felt to be signs of treatment failure or re-obstruction.
Time to re-stricturing on imaging, endoscopic re-dilation or surgery were considered acceptable and optimal long-term endpoints in a clinical trial of an anti-fibrotic drug. There was uncertainty about time to symptom recurrence as an optimal endpoint for failure of stricture therapy after initial response. A trial endpoint for an anti-fibrotic in stricturing Crohn's disease was recommended to include cross-sectional imaging, endoscopy and clinical symptoms (Table S5 ).
| Procedure preparation and reporting of cross-sectional imaging
To standardise procedure preparation and reporting, panelists assessed the appropriateness of cross-sectional imaging procedures.
These results can be found in Table S5 and Appendix S1.
| Expert consensus-based development of clinical trial prototype
Based on items considered appropriate by the CONSTRICT group, we propose a clinical trial outline to be used in the first anti-fibrotic trial in CD (Figure 1) . Primary prevention of a stricture is a large unmet clinical need that novel anti-fibrotic therapies may address.
However, the duration from CD diagnosis to stricture formation can be several years 27, 28 and there is a lack of validated biomarkers to risk stratify patients. 29, 30 Hence, pharmaceutical companies are unlikely to embark on primary prevention trials during the first wave of anti-fibrotic drug development. The panelists therefore felt that eligible patients should be clinically symptomatic, with single, na€ ıve or anastomotic ileal strictures that are in reach of endoscopy and confirmed on cross-sectional imaging (CT or MR enterography). This approach was chosen since the current "gold standard" (surgical specimen analysis) is not feasible in this situation and mucosal biopsy specimen is superficial and will not detect transmural disease.
The panel recommended the inclusion of only symptomatic strictures given that new anti-fibrotic agents are likely to have limited safety data. Therefore, patients and investigators would be reluctant to participate in a trial of therapy that did not offer the possibility of improving symptoms. Furthermore, it is highly unlikely any regulatory agency would agree to a trial evaluating asymptomatic patients at this juncture. Stricture presence on cross-sectional imaging should require all 3 identified features: localised luminal narrowing (luminal diameter reduction of at least 50%), bowel wall thickening (increase in wall thickness of 25%) and pre-stenotic dilation (luminal diameter less than 3 cm). Patients with internal penetrating disease should be excluded, as internal penetrating disease associated with stricturing disease is an indication for surgery. 29 On the basis of these 3 criteria, all eligible patients should initially receive optimal anti-inflammatory therapy to control symptoms and treat mucosal healing 31 with or without endoscopic balloon dilation (using graded-through-the-scope balloons). The maximal diameter of balloon should be 18 mm with a minimal inflation time of 1 minute.
Strictures longer than 5 cm should not be dilated. Anti-inflammatory therapy optimisation should be performed based on a pre-specified algorithm that reflects optimal standard of care. If patient symptoms improve or subside within 12 weeks, the patients should undergo MRE with inclusion of experimental sequences, such as delayed enhancement or magnetisation transfer. The technical details about preparation for MR can be found in Table S5 and Appendix S1. If While there is high accuracy for the detection of inflammation on cross-sectional imaging, 18 currently no imaging technique is able to accurately measure the amount of fibrosis in a stricture. 29 Given that anti-fibrotic therapy approaches may modulate the inflammatory component of a stricture, 1 serial objective parameters of inflammatory activity (ie, serum and faecal biomarkers) throughout the observation should also be collected. This process will facilitate the greatest possible distinction between the anti-fibrotic vs anti-inflammatory effects of an anti-fibrotic drug. This distinction is important as inflammation may be necessary for the development of fibrosis;
however, the progression of fibrosis may become independent of inflammation as the disease progresses. Twenty-four weeks is considered the optimal time point to evaluate treatment success on cross-sectional imaging and ileocolonoscopy. is not meant to be used in totality for a clinical trial endpoint. Ultimately, any PRO item must be patient-derived; however, the procedure we completed is a recommended exercise as a prelude to PRO development, an extensive and iterative process that may require several years.
| DISCUSSION
The strength of our study lies in the inclusion of internationally recognised IBD radiologists and clinical experts and adoption of rigorous methodology to minimise bias. The individual items are not meant to be read in isolation (eg, individual diagnostic modalities to detect a stricture), and while some items were rated highly (eg, MRE), they may not perform with perfect accuracy. Additionally, it may be advantageous to combine items, for instance cross-sectional imaging and symptoms, given the relevance of the latter in clinical practice.
In conclusion, we performed an international consensus process using modified RAND/UCLA appropriateness methodology to standardise CD stricture definitions, inclusion criteria and endpoints for use in routine clinical practice. Based on the items considered appropriate, we constructed a prototypic clinical trial design to be shared with the scientific community as a starting point for future investigations. Initiatives are underway to determine reliability of radiologic items identified in the current study and to create a PRO tool specifically for ileal CD-associated strictures. The ultimate goal is the development of a fully validated set of criteria for use in clinical practice and in drug development.
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